Cyanocapture
Founded 2021 · 12 employees on LinkedIn · 1 known investors
CyanoCapture develops a synthetic biology platform using genetically engineered photosynthetic cells that convert CO2 into high-value molecules such as enzymes, growth factors, peptides, bioplastics, and drug compounds. The company targets biomanufacturing and critical supply chain applications through a zero-sugar, CO2-based production process.
Investors · 1
Frequently asked questions
- What does Cyanocapture do?
- CyanoCapture develops a synthetic biology platform using genetically engineered photosynthetic cells that convert CO2 into high-value molecules such as enzymes, growth factors, peptides, bioplastics, and drug compounds. The company targets biomanufacturing and critical supply chain applications through a zero-sugar, CO2-based production process.
- Who are Cyanocapture's investors?
- Cyanocapture's investors include Moonstone Venture Capital.